List view / Grid view
Minoryx Therapeutics and the Neuraxpharm Group enter into a license agreement for the European rights to leriglitazone, which is currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD).
The Parenteral Drug Association (PDA) is excited to host its 4th Annual European Meeting.
Regulatory reforms and harmonisation reported as key drivers of industry in China.
A study has found that the FDA failed to design and implement an effective monitoring program for Transmucosal Immediate-Release Fentanyls...
A policy has been implemented to aid companies in the formulation, production and manufacture of generic drugs, especially when the originals are expensive...
Draft guidance has been released to offer advice on the new CDER program for the recognition of voluntary consensus standards relating to pharma quality...
The FDA has approved the first specific therapy for the rare blood clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP)...
A number of drugs currently in their late stages in the development process could see competition for nusinersen, the only current SMA treatment, rise...
The FDA has approved the first ever non-chemotherapy combination treatment using ibrutinib and obinutuzumab for the most common form of adult leukaemia...
Dr Scott Gottlieb highlighted how brand reference drug companies voluntarily withdraw their marketing applications and stopped updating their labelling...
The FDA has updated its Opioid Analgesic REMS to ensure caregivers and patients use opioids effectively...
A team of researchers have found that drugs increase in price twice as fast during shortages than if there were not supply and demand imbalances...
Some drugs with active ingredient valsartan have been recalled due to presence of impurity NMDA...
Today, the U.S. Food and Drug Administration cleared the first magnetic resonance imaging (MRI) device specifically for neonatal brain and head imaging in neonatal intensive care units (NICU)...
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
EB-101 is the company's lead gene therapy program for patients suffering with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of...
